A Clinical Study of T3011 in Subjects With Advanced Melanoma
ConditionAdvanced Melanoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorShanghai Pharmaceuticals Holding Co., Ltd
About this trial
This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.
Eligibility criteria
Qualifiers
Subjects with advanced melanoma;
At least one measurable lesion;
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
Expected survival > 12 weeks;
Disqualifiers
Subjects who have received other antitumor therapy within the prescribed time prior to the first dose;
Subjects with a history of other malignancies within the prescribed time prior to the start of study treatment.
At screening, subjects with a history or evidence of high risk cardiovascular disease;
Subjects with persistent or active infection requiring intravenous anti-infective therapy;
Trial design
Treatments tested in this trial
- T3011
Treatment groups
42 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov